Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGNGlobeNewsWire • 09/17/26
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's DiseaseGlobeNewsWire • 09/16/26
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/09/26
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)Business Wire • 09/03/26
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in ChinaGlobeNewsWire • 09/03/26
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)GlobeNewsWire • 09/01/26
Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's DiseaseGlobeNewsWire • 08/31/26
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track NowZacks Investment Research • 08/27/26
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's DiseaseGlobeNewsWire • 08/24/26
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's DiseasePRNewsWire • 08/24/26
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?Zacks Investment Research • 08/20/26
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease PortfolioBenzinga • 07/29/26
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance RaisedZacks Investment Research • 07/29/26